Alejandro Losada

TL;DR: In this article, the authors showed that plitidepsin (aplidin) possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5.

TL;DR: AplidinTM induced growth arrest and apoptosis in human MDA-MB-231 breast cancer cells at nanomolar concentrations and induced apoptosis and activated EGFR, JNK, and p38 MAPK in two cell lines derived from human renal cancer, a neoplasia that is highly refractory to chemotherapy.

TL;DR: It is demonstrated that protein kinase C delta (PKC-δ) mediates the cytotoxic effect of Aplidin™ and that it is concomitantly processed and activated late in the apoptotic process by a caspase mediated mechanism.

TL;DR: It is demonstrated that plitidepsin exerts its antitumor activity by targeting eEF1A2, one of the isoforms of the alpha subunit of the eukaryotic Elongation Factor 1, which is endowed with oncogenic properties, favoring tumor cell proliferation while inhibiting apoptosis.

TL;DR: This review outlines the current knowledge of plitidepsin activity, with a primary focus on the molecular mechanisms of action of the compound.